Fig. 1: Schematic illustration of organoids as a human-derived, physiologically relevant ex vivo platform that faithfully recapitulates the complex tumor microenvironment in a cancer- and patient-specific manner. | npj Biomedical Innovations

Fig. 1: Schematic illustration of organoids as a human-derived, physiologically relevant ex vivo platform that faithfully recapitulates the complex tumor microenvironment in a cancer- and patient-specific manner.

From: Organoid: a promising solution to current challenges in cancer immunotherapy

Fig. 1

This platform integrates high-throughput screening, high-dimensional systems analyses to study tumor-immune interactions while mimicking the temporal dynamics. These unique features enable the evaluation of personalized therapies, addressing key challenges in cancer immunotherapy and accelerating the development of next-generation treatments. HLA human leukocyte antigen, TCR T cell receptor. Created in part with BioRender.com.

Back to article page